Use of identical assay conditions for cocaine analog binding and dopamine uptake to identify potential cocaine antagonists

Drug and Alcohol Dependence

Volumn 48, Issue 1, 1997, Pages 43-50

  Slusher, Barbara S ^a   Tiffany, Carol W ^a   Olkowski, Jennifer L ^a   Jackson, Paul F ^a  

^a GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

3H 2 carbomethoxy 3 (fluorophenyl)tropane; CHO cells; Cocaine; Cocaine antagonists; Dopamine transporter

Indexed keywords

AMILORIDE; ANTIDEPRESSANT AGENT; ANTIMALARIAL AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLOROQUINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CINCHOCAINE; COCAINE; COCAINE DERIVATIVE; DESIPRAMINE; DIPERDIPINE; DIURETIC AGENT; DOPAMINE; DOPAMINE TRANSPORTER; DYCLONINE; IMIPRAMINE; LOCAL ANESTHETIC AGENT; LOPERAMIDE; N (2 METHYLAMINOETHYL) 5 ISOQUINOLINESULFONAMIDE; NEUROLEPTIC AGENT; PINDOLOL; PROCAINE; PROTEIN KINASE C INHIBITOR; PROTRIPTYLINE; TOLPERISONE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DOPAMINE UPTAKE; DRUG DEPENDENCE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SELECTIVITY; EUPHORIA; ISOTOPE LABELING; KINETICS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; BINDING, COMPETITIVE; CARRIER PROTEINS; CHO CELLS; COCAINE; CRICETINAE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; RADIOLIGAND ASSAY; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA; CRICETINAE; CRICETULUS GRISEUS; EUPHORIA;

EID: 0030767706     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(97)00102-6     Document Type: Article

References (20)

1. 3H]mazindol. J. Pharmacol. Exp. Ther. 253:1990;1206-1214.
2. Buck K., Amara S. Chimeric dopamine-norepinephrine transporters delineate structural domains influencing selectivity for catecholamines and 1-methyl-4-phenylpyridinium. Proc. Natl. Acad. Sci. USA. 91:1994;12584-12588.
3. Committee to Study Medication Development and Research at the National Institute on Drug Abuse, 1995. Extent of illicit drug use. In: Fulco, C.E., Liverman, C.T., Earley, L.E., (Eds.), Development of Medications for the Treatment of Opiate and Cocaine Additions: Issues for the Government and Private Sector. National Academy Press, Washington, DC, pp. 36-37.
4. Committee to Study Medication Development and Research at the National Institute on Drug Abuse, 1995. Executive summary. In: Fulco, C.E., Liverman, C.T., Earley, L.E., (Eds.), Development of Medications for the Treatment of Opiate and Cocaine Additions: Issues for the Government and Private Sector. National Academy Press, Washington, DC.
5. Deutsch H., Shi Q., Schweri M. Synthesis and pharmacology of potential cocaine antagonists: SAR studies of aromatic ring substituted methylphenidate analogs. J. Med. Chem. 39:1996;1201-1209.
6. Giros B., Jaber M., Jones S., Wightman R.M., Caron M. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 379:1996;606-612.
7. Giros B., Wang Y.M., Suter S., McLeskey S., Pifl C., Caron M. Delineation of discrete domains for substrate, cocaine, and tricyclic antidepressent interactions using chimeric dopamine-norepinephrine transporters. J. Biol. Chem. 23:1994;15985-15988.
8. 3H]mazindol binding sites from alkylation by N-ethylmaleimide. Eur. J. Pharmacol. 227:1992;411-415.
9. Kitayama S., Shimada S., Xu H., Markham L., Donovan D.M., Uhl G.R. Dopamine transporter site-directed mutations differentially alter substrate transport and cocaine binding. Proc. Natl. Acad. Sci. USA. 89:1992;7782-7785.
10. Krueger B.K. Kinetics and block of dopamine uptake in synaptosomes from rat caudate nucleus. J. Neurochem. 55:1990;260-267.
11. Kuhar M.J., Ritz M.C., Boja J.W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Pharmacol. Sci. 14(7):1991;299-302.
12. McElvain J.S., Scenk J.O. A multisubstrate mechanism of striatal dopamine uptake and its inhibition by cocaine. Biochem. Pharmacol. 43:1992;2189-2199.
13. Munson P.J., Rodbard D. LIGAND: A versatile computerized approach for characterization of ligand binding systems. Anal. Biochem. 107:1984;220-239.
14. Reith M.E.A., Xu C., Zhang L., Coffey L.L. Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in cells expressing the cloned human dopamine transporter. Naunyn-Schmiedeberg's Arch. Pharmacol. 354(3):1996;295-304.
15. 3H]DA-uptake-inhibition to transporter-binding-inhibition ratios for the in vitro evaluation of putative cocaine antagonists. Life Sci. 53:1993;PL267-272.
16. Simoni D., Stoelwinder J., Kozikowski A., Johnson K., Bergman J., Ball R. Methoxylation of cocaine reduces binding affinity and produces compounds of differential binding and dopamine uptake inhibitory activity: discovery of a weak cocaine 'antagonist'. J. Med. Chem. 36:1993;3975-3977.
17. Taylor D., Ho B.T. Comparison of inhibition of monoamine uptake by cocaine, methylphenidate and amphetamine. Res. Commun. Chem. Pathol. Pharmacol. 21:1978;67.
18. Woodward J.J., Compton D.M., Balster R.L., Martin B.R. In vitro and in vivo effects of cocaine and selected local anesthetics on the dopamine transporter. Eur. J. Pharm. 277(1):1995;7-13.
19. Xu C., Coffey L.L., Reith M.E.A. Translocation of dopamine and binding of WIN 35,428 measured under identical conditions in rat synaptosomal preparations. Biochem. Pharmacol. 49:1995;339-350.
20. Zimanyi I., Lajtha A., Reith M.E.A. Comparison of characteristics of dopamine uptake and mazindol binding in mouse striatum. Naunyn-Schmiedeberg's Arch. Pharmacol. 340:1989;626.